

REMARKS

Entry of the amendment is requested.

With respect to point 1, all claims now recite a definite or indefinite article, and claim 75 is presented in independent form.

With respect to point 2, a Terminal Disclaimer relative to U.S. Patent No. 5,804,381 accompanies this amendment.

Claim 74 is amended to recite polypeptide, thereby abrogating point 3.

All issues have been addressed. Allowance is believed in order.

The Commissioner is hereby authorized to deduct any fees associated with this filing from Deposit Account No. 500624.

Respectfully submitted,

By 
Norman D. Hanson
Registration No.: 30,946
FULBRIGHT & JAWORSKI L.L.P.
666 Fifth Avenue
New York, New York 10103
(212) 318-3000
(212) 318-3400 (Fax)
Attorney for Applicant

Attachment: Terminal Disclaimer